Elicio Therapeutics Reports Complete Responses in Metastatic Pancreatic Cancer After ELI-002 7P and Nivolumab

Complete responses in metastatic pancreatic cancer remain rare enough, published rates sit at 0% to 8% across chemotherapy, checkpoint inhibitor, and RAS inhibitor regimens, that three confirmed cases emerging from a single Phase 2 cohort carry meaningful signal for development teams tracking mKRAS-targeted immunotherapy platforms. Elicio Therapeutics disclosed on June 17, 2026, that three patients who progressed following treatment in the AMPLIFY-7P Phase 2 study subsequently achieved confirmed complete radiographic and complete metabolic responses after receiving nivolumab-based therapy, with concurrent normalization of CA19-9 tumor biomarker levels.

All three patients were microsatellite stable (MSS) / mismatch repair proficient (MMR-p), a molecular subtype historically resistant to immune checkpoint blockade. Two maintained complete responses for at least eight months; one remains in complete response at more than 13 months. Persistent mKRAS-specific T cell activity was documented across all three cases, which Elicio interprets as mechanistic support for the hypothesis that ELI-002 7P-induced immune priming may sensitize tumors to subsequent anti-PD-1 therapy.

The observations are preliminary and derive from post-study follow-up rather than a prospectively designed combination arm, a distinction that regulatory and clinical operations leads will need to weigh carefully when assessing evidentiary weight. Elicio has stated it intends to continue monitoring additional AMPLIFY-7P participants following a similar treatment course, which will expand the observational dataset ahead of any formal combination study.

For CMC and manufacturing planning teams, the near-term development read is straightforward: Elicio intends to initiate a Phase 1 study in first-line metastatic PDAC evaluating ELI-002 7P in combination with checkpoint inhibition, subject to funding. ELI-002 7P is a lymph-node-targeting amphiphilic lipid-conjugated peptide platform, and any Phase 1 expansion will require early alignment on process validation parameters, batch consistency, and supply agreements with contract manufacturing partners capable of handling lipid-peptide conjugate formats under 21 CFR Part 211 GMP standards.

Elicio has also indicated that Phase 1 findings will inform the design of a future Phase 3 trial in adjuvant PDAC, meaning the combination data generated in the metastatic setting could directly shape registration-enabling study protocols. A virtual key opinion leader event is scheduled for June 24, 2026, at 1:00 PM ET, where the company plans to discuss the observations in further detail.

The confirmatory Phase 1 study's ability to enroll and execute on schedule will serve as the first measurable checkpoint for whether these preliminary complete response observations translate into a viable regulatory pathway for ELI-002 7P in metastatic PDAC.

Source: Elicio Therapeutics via GlobeNewswire, June 17, 2026. Virtual KOL event: June 24, 2026, 1:00 PM ET.